Pressmeddelande

Integrum’s OPRA™ Implant System gets FDA approval for clinical study on below-knee amputations

Cision Publicerad: 30 Oct 2023 08:32

Mölndal, Sweden – October 30, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company’s OPRA™ Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US

The clinical study will be important for the future approval of the OPRA™ Implant System on the below-knee amputation level, which is the most frequent amputation level. The study will be performed by the Walter Reed National Military Medical Center.

“This is an important milestone in the expansion of indications for our OPRA™ Implant System.” said Rickard Brånemark, CEO of Integrum.

Bifogade filer

2023-10-30 Integrum PR IDE TTAhttps://mb.cision.com/Public/17531/3865375/ae332572d5827e27.pdf

Nyheter om Integrum

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!